November 21, 2024
Identifying robust preclinical models for cholangiocarcinoma is essential for the development of targeted therapies. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity. The Crown Bioscience cholangiocarcinoma PDX collection consists of several models which provide an accurate approach to predicting an agents efficacy prior to entering the clinic. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
CC0449 | Cholangiocarcinoma | ECC | Mucinous adenocarcinoma from mesenterium and tumor embolus in common bile duct. | CLICK TO VIEW |
CC11307 | Cholangiocarcinoma | ADC | Cholangiocarcinoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 80% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
CC1470 | Cholangiocarcinoma | ICC | Cholangiocellular carcinoma. The tumor forms irregular glandular, cribriform or funicular structures and has an infiltrative growth pattern. The neoplastic cells show cubic or columnar form with nuclear atypia. Mild fatty degeneration and mild chronic inflammation may be seen in peripheral hepatic tissue. | CLICK TO VIEW |
CC6204 | Cholangiocarcinoma | ICC | Intrahepatic cholangiocarcinoma, grade II-III | CLICK TO VIEW |
CC6205 | Cholangiocarcinoma | ICC | Intrahepatic cholangiocarcinoma, poorly differentiated | CLICK TO VIEW |
CC6216 | Cholangiocarcinoma | NA | Poorly differentiated cholangiocarcinoma | CLICK TO VIEW |
CC6279 | Cholangiocarcinoma | ICC | Left lobe of liver: intrahepatic cholangiocarcinoma, moderately differentiated. | CLICK TO VIEW |
CC6600 | Cholangiocarcinoma | ICC | Left lobe of liver: cholangiocarcinoma, grade III, peripheral hepatic tissue: G1S3. Three of eight lymph nodes involved by metastatic carcinoma (3/8). IHC result: AFP(-), Hepa(-), CK7(+++), CK19(+++), CD34(blood vessel +), GPC3(-), Thromblin(-), IL-2(-), Ki67(30%+), CD8( about 15/HPF), OPN(++), CD151(-), CD117(-). | CLICK TO VIEW |
CC6604 | Cholangiocarcinoma | ICC | Intrahepatic cholangiocarcinoma, grade II, with massive necrosis. Cancer embolus presents in vessel, incomplete septal cirrhosis presented in periphery hepatic tissues, G1S3.IHC results: AFP(-), Hepa(-), CK7(90%++), CK19(100%++), CD34(rich vascularity ), KI67(40%+), CD8(lymphocyte +), OPN(100%+), CD151(-), EPCAM(-), ARG-1(-), CD56(-), CD117(-). | CLICK TO VIEW |
CC6607 | Cholangiocarcinoma | ICC | Middle lobe of liver: adenocarcinoma, cholangiocarcinoma on basis of IHC results, grade II-III. IHC results: Hepa(-), CK7(++), CK19(++), CD34(abundant blood sinus), CPC3(-), KI67(30%+), CD56(part +), CD117(-), HSP70(+), GS(scattered +), LCK(++). | CLICK TO VIEW |
CC6609 | Cholangiocarcinoma | ICC | Left lobe of liver: intrahepatic cholangiocellular carcinoma (4 focus) grade II-III, with massive necrosis and tumor spread focus, peripheral hepatic tissues showed nodular cirrhosis G2S1. All lymph nodes are benign (0/5). | CLICK TO VIEW |
CC6625 | Cholangiocarcinoma | ICC | Cholangiocarcinoma, grade III, G2S1, with massive necrosis, and part of squamous metaplasia.IHC result: AFP(-), Hepa(-), CK7(100%++~+++), CK19(100%++~+++), CD34(vessel +), Ki-67(30%+), GP73(90%++), TG(-), P63(portion +), HCK(100%++~+++). | CLICK TO VIEW |
CC6637 | Cholangiocarcinoma | ICC | Right lobe of liver: Intrahepatic cholangiocellular adenocarcinoma, grade II-III, with necrosis. Peripheral hepatic tissues showed nodular cirrhosis G1S0~1. IHC results: AFP(-), Hepa(-), CK7(++), CK19(++), CD34(blood vessel +), Villin(+), CDX-2(-), CK20(-), Ki67(40%+), CA199(++), CEA(++). | CLICK TO VIEW |
CC6638 | Cholangiocarcinoma | ICC | Left lobe of liver: intrahepatic cholangiocarcinoma, grade II, with massive necrosis. Peripheral hepatic tissues showed nodular cirrhosis G3S1. IHC results: AFP(-), Hepa(-), CK7(100%+++), CK19(100%+++), CD34(blood vessel +), Ki67(30%+), GS(small +), GPC-3(-), HSP70(40%++), CD151(-), OPN(80%++), Thrombin(-), GP73(100%+++), CD8(1 lymphocyte/HPF). | CLICK TO VIEW |
CC6639 | Cholangiocarcinoma | ICC | Liver: cholangiocarcinoma, grade II. Peripheral hepatic tissues did not show nodular cirrhosis G1S0. IHC result: AFP(-), Hepa(-), CK7(100%+++), CK19(100%+++), CD34(blood vessel +), Ki67(30%+), GS(70%+), GPC-3(-), HSP70(80%+~++). | CLICK TO VIEW |
CC6644 | Cholangiocarcinoma | Adenocarcinoma | NA | CLICK TO VIEW |
CC6645 | Cholangiocarcinoma | ICC | Right lobe of liver: cholangiocarcinoma, grade II-III, with massive necrosis. Peripheral hepatic tissues showed nodular cirrhosis (G1S2). One of two lymph nodes involved by metastatic carcinoma (1/2). | CLICK TO VIEW |
CC6658 | Cholangiocarcinoma | ICC | Right lobe of liver: adenocarcinoma, grade II, consider bile duct origin. Peripheral hepatic tissues showed nodular cirrhosis G2~3,S2~3.IHC results: AFP(-), Hepa(-), CK7(+++), CK19(++), CD34(blood vessel +), GP73(++), Thromblin(-), IL-2(-), Ki67(70%+), CD8(2/HPF), OPN(70%+), GS(-), HSP70(+~++), CD151(-), GPC-3(-). | CLICK TO VIEW |
CC6679 | Cholangiocarcinoma | ADC | Left lobe of liver: cholangiocarcinoma, grade II-III, periphery hepatic tissues, G1S1. | CLICK TO VIEW |
CC6690 | Cholangiocarcinoma | ADC | Liver: cholangiocarcinoma, grade II-III | CLICK TO VIEW |
CC6702 | Cholangiocarcinoma | ADC | Right lobe of liver: cholangiocarcinoma, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis (G1S3). | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy